Isomorphic Labs Raises $600M to Advance AI Drug Design and Internal Pipeline
Isomorphic Labs has secured $600 million in its first external funding round to accelerate the development of its AI-based drug design engine and support the advancement of internal therapeutic programs into the clinic. The round was led by Thrive Capital, with participation from GV and follow-on investment from Alphabet, the company’s founding backer.
Founded in 2021 by Sir Demis Hassabis by Demis Hassabis as a London-based spin-off from Alphabet’s DeepMind, Isomorphic Labs focuses on integrating frontier AI research with drug discovery. The company has built a suite of AI models that together form a unified drug design engine capable of operating across multiple therapeutic areas and drug modalities. Among its key technical milestones is AlphaFold 3—developed in collaboration with Google DeepMind—which was released in May 2024 and is designed to predict the structure and interactions of biological molecules with high accuracy.
According to the company, the newly raised capital will fund further AI model innovation, expand its internal R&D programs—primarily in oncology and immunology—and support growth of its London and Lausanne-based team. In addition to its proprietary pipeline, Isomorphic Labs has established partnerships with pharmaceutical companies including Eli Lilly and Novartis, with the latter recently expanding the scope of its collaboration.
The company stated that the funding will enable continued scaling of its computational platform and support the long-term goal of developing AI-driven methods for discovering and designing new treatments across disease areas.
Cover image: Googe DeepMind
Topic: Biotech Ventures
